Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0043-1761263
Radiation Recall Dermatitis in Breast Cancer Patient after Trastuzumab: A Case Report with Review of Literature
Funding None.![](https://www.thieme-connect.de/media/10.1055-s-00050348/202303/lookinside/thumbnails/10-1055-s-0043-1761263_221800896-1.jpg)
Abstract
Radiation recall dermatitis (RRD) is an extremely rare phenomenon. A variety of factors such as antineoplastic agents, pharmaceutical agents, physical and environmental factors have been proposed to be the underlying cause of RRD. Only a handful cases have been reported till date, where trastuzumab is sought to be the triggering agent. The presentation of RRD varies from mild erythematous to extensive confluent dermatitis, resolving over a period of 1 to 2 weeks with conservative management. Most of the patients tend to tolerate rechallenge well without showing reappearance. We hereby describe a lady with breast cancer having RRD following administration of trastuzumab. She developed reaction 28 days post-radiotherapy and managed conservatively. Furthermore, she was rechallenged with the same dose, that she tolerated very well, without any reappearance. Hence, an acquaintance of the clinicians to this rare entity is essential for timely diagnosis and appropriate management.
Publication History
Article published online:
12 May 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Azria D, Magné N, Zouhair A. et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005; 31 (07) 555-570
- 2 Burris III HA, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010; 15 (11) 1227-1237
- 3 Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001; 59 (03) 237-245 http://www.ncbi.nlm.nih.gov/pubmed/11369064
- 4 D'Angio GJ, Farber S, Maddock CL. Potentiation of x-ray effects by actinomycin D. Radiology 1959; 73 (02) 175-177
- 5 Bentzen SM, Agrawal RK, Aird EG. et al; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9 (04) 331-341
- 6 Ben-Yosef H. Radiation recall dermatitis. Lancet 1996; 348 (9037): 1321 http://www.ncbi.nlm.nih.gov/pubmed/8909413
- 7 Guarneri C, Guarneri B. Radiation recall dermatitis. CMAJ 2010; 182 (03) E150-E150
- 8 Cho S, Breedlove JJ, Gunning ST. Radiation recall reaction induced by levofloxacin. J Drugs Dermatol 2008; 7 (01) 64-67 http://www.ncbi.nlm.nih.gov/pubmed/18246700
- 9 Jain S, Agarwal J, Laskar S, Gupta T, Shrivastava S. Radiation recall dermatitis with gatifloxacin: a review of literature. J Med Imaging Radiat Oncol 2008; 52 (02) 191-193
- 10 Le Scodan R, Wyplosz B, Couchon S, Housset M, Laccourreye O. UV-light induced radiation recall dermatitis after a chemoradiotherapy organ preservation protocol. Eur Arch Otorhinolaryngol 2007; 264 (09) 1099-1102
- 11 Ng AWY, Wong FCS, Tung SY. S K O. Nimesulide–a new trigger of radiation recall reaction. Clin Oncol (R Coll Radiol) 2007; 19 (05) 364-365
- 12 Marchand A, Georgin-Mège M, Cellier P, Martin L, Avenel-Audran M, Le Corre Y. Exemestane-induced radiation recall dermatitis and morbilliform rash. J Dermatol 2016; 43 (05) 575-576
- 13 Levy A, Hollebecque A, Bourgier C. et al. Targeted therapy-induced radiation recall. Eur J Cancer 2013; 49 (07) 1662-1668
- 14 Alsabbak H, Aljuboori Z, Spierer M, Klein P. The association of adjuvant trastuzumab (Herceptin) with radiation recall dermatitis: a case study. J Cancer Sci Ther 2013; 05 (12) DOI: 10.4172/1948-5956.1000236.
- 15 Moon D, Koo JS, Suh C-O, Yoon CY, Bae J, Lee S. Radiation recall dermatitis induced by trastuzumab. Breast Cancer 2016; 23 (01) 159-163
- 16 Shrimali RK, McPhail NJ, Correa PD, Fraser J, Rizwanullah M. Trastuzumab-induced radiation recall dermatitis–first reported case. Clin Oncol (R Coll Radiol) 2009; 21 (08) 634-635
- 17 Lee HE, Jeong NJ, Lee Y. et al. Radiation recall dermatitis and pneumonitis induced by trastuzumab (Herceptin®). Int J Dermatol 2014; 53 (03) e159-e160 http://www.ncbi.nlm.nih.gov/pubmed/24716200
- 18 Chung C, Stuart D, Keyes M. Radiation recall reaction induced by adjuvant trastuzumab (Herceptin). Case Rep Med 2009; 2009: 307894 DOI: 10.1155/2009/307894.
- 19 Anupama C, Vinayak V, Anuradha H, Maka V. Trastuzumab induced radiation recall dermatitis: an interesting case. Int J Basic Clin Pharmacol 2018; 7 (12) 2465-2467
- 20 Slamon DJ, Leyland-Jones B, Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11) 783-792
- 21 Corbin KS, Breen WG, Strauss JB. Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1). Clin Transl Radiat Oncol 2020; 24: 99-101
- 22 Jeter MD, Jänne PA, Brooks S. et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53 (02) 394-400
- 23 Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 2002; 6 (06) 535-540
- 24 Saif MW, Black G, Johnson M, Russo S, Diasio R. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemother Pharmacol 2006; 58 (06) 771-775
- 25 Hird AE, Wilson J, Symons S, Sinclair E, Davis M, Chow E. Radiation recall dermatitis: case report and review of the literature. Curr Oncol 2008; 15 (01) 53-62 http://www.ncbi.nlm.nih.gov/pubmed/18317586
- 26 Khanna NR, Kumar DP, Laskar SG, Laskar S. Radiation dermatitis: an overview. Indian J Burns 2013; 21 (01) 24 DOI: 10.4103/0971-653X.121877.